Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

by | Aug 15, 2026 | Clinical Trials | 0 comments

​ Conditions: Open Angle Glaucoma (OAG); NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)

Interventions: Genetic: ER-100 epigenetic therapy

Sponsors: Life Biosciences Inc.

Not yet recruiting Conditions: Open Angle Glaucoma (OAG); NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Interventions: Genetic: ER-100 epigenetic therapy
Sponsors: Life Biosciences Inc.
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *